ABSTRACT
OBJECTIVE: External radiation therapy has been available since 2011 for small animals at the University of Munich. The aim of the study was to evaluate the quality of life of treated pets and the satisfaction of their owners. MATERIAL AND METHODS: The questionnaire was sent to the owners of all the pets (n = 91) that had undergone primary or adjuvant radiotherapy at the Clinic of Small Animal Medicine, University of Munich, since April 2011. RESULTS: The questionnaire was returned by 68 (74.7%) owners. According to their assessment, the quality of life improved in 41 cases (60.3%) after treatment where- as in 13 patients (19.1%) a decline was described. The majority of owners (88.2%) would have decided for repeated radiation therapy. CONCLUSION: Improvement of the animals' quality of life is related to a high satisfaction (83.8%) of the owners (p = 0.003) and their positive attitude towards radiotherapy (p = 0.027). CLINICAL RELEVANCE: Analyses showed that for these owners, the treatment was a worthwhile therapy despite it requiring much time and money.
Subject(s)
Cat Diseases/radiotherapy , Dog Diseases/radiotherapy , Pets , Radiotherapy, Adjuvant/veterinary , Animals , Cat Diseases/psychology , Cats , Dog Diseases/psychology , Dogs , Humans , Quality of Life , Surveys and QuestionnairesABSTRACT
The tumour suppressor p53 is commonly detected in tissues of companion animals by means of antibodies raised against the human protein. The following three-step procedure was devised to test the suitability of such antibodies for immunohistochemistry on canine tissues. (1) Western blot and immunohistochemical analyses on bacterially expressed recombinant canine protein to assess human-to-canine cross-reactivity. (2) Immunohistochemistry of cultured, UVB-irradiated canine keratinocytes to evaluate suitability for detection of endogenous p53. (3) Immunohistochemistry on tissue arrays to further substantiate suitability of the antibodies on a panel of normal and neoplastic human and canine tissues. Five of six antibodies cross-reacted with recombinant canine p53. Three of these (PAb122, PAb240, CM-1) also immunolabelled stabilized wild type p53 in cell cultures and elicited a consistent, characteristic labelling pattern in a subset of tumours. However, two alternative batches of polyclonal antibody CM-1 failed to detect p53 in cell cultures, while showing a characteristic labelling pattern of a completely different subset of tumours and unspecific labelling of normal tissues. The test system described is well suited to the selection of antibodies for immunohistochemical p53 detection. The results emphasize the need to include appropriate controls, especially for polyclonal antibodies.
Subject(s)
Antibodies/immunology , Immunohistochemistry/veterinary , Tumor Suppressor Protein p53/immunology , Animals , Apoptosis , Cells, Cultured , Cross Reactions , Dogs , Humans , Immunohistochemistry/methods , Keratinocytes/cytology , Keratinocytes/metabolism , Recombinant Proteins/immunology , Tumor Suppressor Protein p53/metabolismABSTRACT
Abstract The aim of this study was to evaluate if hypoxia in feline fibrosarcomas can be detected. This was done using positron emission tomography (PET), two hypoxia tracers and polarographic pO(2) measurements. Of the seven cats included, five received [(18)F]-fluoromisonidazole and two 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide. Perfusion was evaluated with [(15)O]-H(2)O (n = 4) and with contrast-enhanced power Doppler ultrasonography (n = 5). Hypoxia was detected in three cats. Polarographic pO(2) measurements did not confirm PET results. In the ultrasonographic evaluation, low vascularity and low perfusion were seen with a peripheral vascular pattern and no perfusion in the centre of the tumour. This was in contrast to the [(15)O]-H(2)O scans, where central perfusion of the tumour was also found. In conclusion, it appears that hypoxia exists in this tumour type. The presence of tumour necrosis and heterogeneous hypoxia patterns in these tumours may explain the found discrepancies between the applied techniques.
ABSTRACT
In human medicine positron emission tomography (PET) is a modern diagnostic imaging method. In the present paper we outline the physical principles of PET and give an overview over the main clinic fields where PET is being used, such as neurology, cardiology and oncology. Moreover, we present a current project in veterinary medicine (in collaboration with the Paul Scherrer Institute and the University Hospital Zurich), where a hypoxia tracer is applied to dogs and cats suffering from spontaneous tumors. Finally new developments in the field of PET were discussed.
Subject(s)
Tomography, Emission-Computed/veterinary , Veterinary Medicine/instrumentation , Veterinary Medicine/methods , Animals , Diagnostic Techniques, Neurological/veterinary , Heart Diseases/diagnosis , Heart Diseases/diagnostic imaging , Heart Diseases/veterinary , Humans , Image Processing, Computer-Assisted , Neoplasms/diagnosis , Neoplasms/diagnostic imaging , Neoplasms/veterinary , Tomography, Emission-Computed/instrumentation , Tomography, Emission-Computed/methodsABSTRACT
Five cats tentatively diagnosed with pituitary adenoma (four cases) or pituitary carcinoma (one case), based on computed tomography (CT) or magnetic resonance imaging, were treated with radiotherapy. Electrons were applied in four cats and electrons and photons in the fifth. Ten to 12 fractions of 3.5 to 4.0 Gy each were delivered on a Monday/Wednesday/Friday schedule. The mean total dose applied was 39 Gy. No severe acute side effects to treatment were seen. Follow-up CT examination was performed in four cats; the mass had disappeared in one cat and remained stable or slightly decreased in size in the other three. The survival times were 5.5, 8.0, 15.0, 18.0 and 20.5 months, with two cats dying of causes unrelated to the tumour. Based on these cases, radiotherapy appears to be a valuable treatment option for feline pituitary tumours.
